Document is current
Any future updates will be listed below
-
Authors
Ohta, Yuki
Taida, Takashi
Ogasawara, Sadahisa
Aizu, Takuma
Konagaya, Takahito
Ota, Mitsunori
Koborita, Ryoko
Suzuka, Ryuji
Ito, Toshiyuki
Ozeki, Yusuke
Furuya, Makoto
Shu, Nobuaki
Horio, Ryosuke
Nagashima, Ariki
Shiratori, Wataru
Yokoyama, Yuya
Nakamura, Masato
Okimoto, Kenichiro
Saito, Keiko
Matsumura, Tomoaki
Nakagawa, Tomoo
Shimazu, Minobu
Sakurai, Yoichi
Yoshimura, Kensuke
Kato, Jun
-
Funding
Funding for this research was provided by:
Chiba Foundation for Health Promotion and Disease Prevention
AbbVie
- License Information
-
More Information
Article History
Received: 20 November 2025
Accepted: 19 May 2026
First Online: 1 June 2026
Competing interests
: Sadahisa Ogasawara received honoraria from Bayer, Eisai, Eli Lilly, Chugai Pharma, AstraZeneca, Takeda, Abbvie, Gilead Sciences, and Merck & Co., Inc., consulting or advisory fees from Bayer, Eisai, Merck & Co., Inc., Chugai Pharma, Eli Lilly, and AstraZeneca, and research grants from Bayer, AstraZeneca, Gilead Sciences, Eli Lilly, and Eisai. Jun Kato received consulting or advisory fees from Takeda Pharmaceutical Company Limited; Pfizer Inc.; Zeria Pharmaceutical Co., Ltd.; Mochida Pharmaceutical Co., Ltd.; Gilead Sciences, Inc.; Mitsubishi Tanabe Pharma Corporation; Janssen Pharmaceutical K.K. (a Johnson & Johnson company); EA Pharma Co., Ltd.; Bristol Myers Squibb K.K.; Johnson & Johnson K.K.; Kissei Pharmaceutical Co., Ltd.; AbbVie Inc.; Japan Medical Dynamic Marketing, Inc. (JIMRO); Sandoz K.K.. Takashi Taida received research grants from AbbVie Inc.. The other authors have no conflicts of interest to declare.
